A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
-
University of Arizona Cancer Center, Tucson, Arizona, United States, 85724
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
University of Colorado Cancer Center, Aurora, Colorado, United States, 80045
Yale Cancer Center, New Haven, Connecticut, United States, 06510
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States, 30322
Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana, United States, 70112
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States, 87131
Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029
Stony Brook University Cancer Center, Stony Brook, New York, United States, 11794
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Criterium, Inc.,
Lajos Pusztai, MD, PRINCIPAL_INVESTIGATOR, Yale University
2027-12-31